Source: International Congress 2017 – Precision medicine approaches in lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
Thierry Berghmans (Bruxelles, Belgium). Precision medicine for lung cancer: new targeted treatments . International Congress 2017 – Precision medicine approaches in lung cancer

Member's Comments

No comment yet.

Related content which might interest you: New and emerging targeted treatments in advanced lung cancer Source: International Congress 2016 – Lung cancer: latest developments in screening and patient management Year: 2016 PG11 Modern approaches in lung cancer diagnostics and therapy Source: Paris 2018 - Educational material Year: 2018 Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing? Source: Eur Respir J 2014; 44: 1011-1022 Year: 2014 Innovative local therapies in lung cancer Source: International Congress 2018 – PG11 Modern approaches in lung cancer diagnostics and therapy Year: 2018 New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Advances in target therapy for lung cancer Source: International Congress 2014 – Ceremony for the ERS Romain Pauwels Research Award 2014 - Clinical Year in Review I Year: 2014 Advances in target therapy in lung cancer Source: Eur Respir Rev 2015; 24: 23-29 Year: 2015 Modern staging in lung cancer: from the current multidisciplinary process to novel approaches Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach Year: 2019 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 TKIs: a new class of drugs in the management of lung cancer Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011 The clinical benefit of personalised medicine in lung cancer Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms Year: 2014 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 New and anticipated therapeutic developments in management of non-small-cell lung cancer Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer Year: 2013 Current place and future of immunotherapy in lung cancer Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016 Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014